Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Sunday's Question of the Day

In your opinion, what justification did the BoD use when granting these new options in addition to their "regular" compensation:

A. enhancement of shareholder value (if they were referring to future enhancements )

E. based on BoD qualification and experience (and has absolutely nothing to do with results)

Share
New Message
Please login to post a reply